retatrutide triple agonist weight loss trial Today, we shared new data from two Phase 3 trials of retatrutide, our investigational agonist. Learn more: https://go.lilly.com/msrz1v Lilly's triple agonist achieves 16.8%

Elkasrawy, M., & Hamrick, M

Doctors also weigh waist circumference, uncontrolled Type 2 diabetes, and family history of metabolic disease

The active compound is tirzepatide, a synthetic peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R)

This is normal physiology reaching a new equilibrium

Eric Xu, Li-Hua Zhao, Dehua Yang & Ming-Wei Wang Source : This study utilized cryo-electron microscopy to elucidate the structural basis of Retatrutides triple agonism at the GLP-1, GIP, and GCG receptors

"We had never saw that," Kushner says